translation agency

NLM AIDSLINE
The immunosubstitutional treatment with thymus extract and cotrimoxazole of anti-HIV-seropositive addicts.
Boron P; Borzuchowska A; Boron-Kaczmarka A; Kramarz P; Kuklik N;
December 30, 1992
Int Conf AIDS. 1992 Jul 19-24;8(3):57 (abstract no. PuB 7053). Unique

OBJECTIVE: The aim of this paper is the estimation of eventual influence of immunomodulor drug-Thymusextract/Dr Ollendiek, Germany/and non-specific anti-inflammatory drug-Cotrimoxazole/Biseptol-Polfa/in selected groups of anti-HIV-seropositive addicts. METHODS: First group included 8 anti-HIV-seropositive addicts with persistent generalised lymphadenopathy/PGL/, which received Thymusextract suppositoria 2 times daily a 1500 mg and Cotrimoxazole 2 times daily a 960 mg. Second group/8 patients/along the same classification received only Cotrimoxazole. In laboratory tests after 2 and 4 weeks of observation they were estimated: percentage of lymphocytes T and B, values of CD4 and CD8, circulating immune complexes/CIC/, complement-fractions C3, C4 and immunoglobulins. RESULTS: In the first group it was observed the range of lymphocytes T 61-71, B 20-27, without essential changes after treatment. The values of complement-fractions C3, C4 after treatment were not differentiated The observed primarily high values of IgG were not changed. In the second group the primarily high IgG-values were not essentially changed after treatment. It was observed the decrease of the C3 and C4 values. The values of CD4 were decreased. CONCLUSIONS: Thymusextract and Cotrimoxazole-treatment may influence the disimmunological status of anti-HIV-seropositive addicts with clinical manifested PGL-syndrome.

Drug Therapy, Combination Human HIV Seropositivity/COMPLICATIONS/IMMUNOLOGY/*THERAPY IgG/ANALYSIS Substance Dependence/*COMPLICATIONS T-Lymphocyte Subsets Thymus Extracts/*ADMINISTRATION & DOSAGE Trimethoprim-Sulfamethoxazole Combination/*ADMINISTRATION & DOSAGE ABSTRACT

www.aegis.org